Brief: Kezar Life Sciences And Everest Medicines Enter Into An Agreement To Develop And Commercialize Zetomipzomib For Lupus Nephritis And Other Potential Indications In Greater China, South Korea And Southeast Asia

Kezar Life Sciences

20/09/2023 23:30

Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES AND EVEREST MEDICINES ENTER INTO AN
AGREEMENT TO DEVELOP AND COMMERCIALIZE ZETOMIPZOMIB FOR LUPUS
NEPHRITIS AND OTHER POTENTIAL INDICATIONS IN GREATER CHINA,
SOUTH KOREA AND SOUTHEAST ASIA
    * KEZAR LIFE SCIENCES INC - KEZAR IS ELIGIBLE TO RECEIVE UP
TO
$132.5 MILLION IN TOTAL PAYMENTS, AS WELL AS TIERED ROYALTIES
    * KEZAR LIFE SCIENCES INC - EVEREST MEDICINES WILL ALSO PAY
TIERED
ROYALTIES ON NET SALES

Source text for Eikon:  ID:nBw1ZQ2la 
Further company coverage:  KZR.O